Impact of Baseline Systolic Blood Pressure on Blood Pressure Changes Following Renal Denervation

Renal denervation (RDN) is a guideline-recommended therapy to reduce blood pressure in patients with uncontrolled hypertension, although uncertainties remain regarding which factors best predict the treatment response. Higher baseline systolic blood pressure (SBP) has been associated with greater subsequent reductions—a phenomenon described by Wilder’s “law of initial value.” This study aimed to quantify the expected SBP changes at 6 months after radiofrequency renal denervation (RDN-RF) according to baseline values.Presion arterial sistólica

The primary endpoint was to determine the relationship between baseline SBP and changes in office and ambulatory SBP at 6 months after RDN-RF. The secondary endpoint included estimating the probability of blood pressure reduction within different ranges (0–20, 20–40 mmHg, etc.) and analyzing this relationship at 12 months.

Study Characteristics

The study pooled data from 3,377 patients with uncontrolled hypertension treated with RDN-RF from multiple clinical trials (SPYRAL FIH, SYMPLICITY HTN-3, SYMPLICITY HTN-Japan, SPYRAL HTN-ON MED, and SYMPLICITY DEFINE). All participants had a baseline SBP ≥140 mmHg and were receiving antihypertensive medication. Mean age was 60±12 years, 41% were women, with a BMI of 31.3±5.9 kg/m²; 38% had type 2 diabetes and 8.4% had a history of myocardial infarction. Baseline office SBP (OSBP) averaged 171.8±20.5 mmHg, and ambulatory SBP (ASBP) 155.9±17.3 mmHg. The mean number of antihypertensive medications was 4.4±1.5. At 6 months, OSBP and ASBP decreased by 16.3±24.0 and 7.5±16.7 mmHg, respectively (p<0.0001), with no clinically significant changes in medication burden (4.3±1.5; p<0.0001).

Read also: AHA 2025 | DAPT-MVD: Extended DAPT vs. Aspirin Monotherapy After PCI in Multivessel Disease.

Linear regression analysis showed a significant correlation between baseline SBP and blood pressure reduction at 6 months: for every 10-mmHg increase in baseline SBP ≥140 mmHg, the average reduction was 5.6 mmHg for office BP (p<0.0001) and 4.3 mmHg for ambulatory BP (p<0.0001). Patients with baseline SBP levels of 150, 160, 170, and 180 mmHg had expected mean reductions of 4.2, 9.8, 15.4, and 21.0 mmHg, respectively. A patient with an SBP of 170 mmHg had a 76.5% probability of experiencing a BP decrease, whereas those with 190 mmHg had an 88.7% probability of reduction and a 62.2% probability of achieving a drop greater than 20 mmHg. Twelve-month analyses confirmed the persistence of this association.

How baseline SBP predicts blood pressure reduction after renal denervation

In conclusion, the higher the baseline SBP, the greater the expected blood pressure reduction at 6 months after RDN-RF. For every 10-mmHg increase in initial SBP, the mean decrease was 5.6 mmHg in office BP and 4.3 mmHg in ambulatory BP. The study confirms that baseline SBP is the strongest and simplest predictor of treatment response.

Original Title: Impact of baseline systolic blood pressure on blood pressure changes following renal denervation.

Reference: Roland E. Schmieder, MD; et al EuroIntervention. 2025;21:e1281–e1287. DOI: 10.4244/EIJ-D-24-01131.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

ACC 2026 | HI-PEITHO: Catheter-directed strategy (EKOS) in intermediate-risk acute pulmonary embolism

The treatment of intermediate-risk pulmonary embolism (PE) continues to be an area of therapeutic uncertainty. The initial PEITHO study (2014) demonstrated a reduction in...

ACVC 2026 | FLASH Registry European Cohort: Mechanical Thrombectomy in Pulmonary Embolism

The management of intermediate-high and high-risk pulmonary embolism (PE) remains an area of therapeutic uncertainty, particularly in patients with right ventricular (RV) dysfunction, in...

AHA/ACC Guideline on the Management of Acute Pulmonary Embolism 2026

The 2026 ACC/AHA guideline for the management of acute pulmonary embolism (PE) introduces a conceptual shift by replacing the traditional “risk-based” classification with an...

FFR Assessment for the Selection of Hypertensive Patients Who Benefit from Renal Stenting

Atherosclerotic renal artery stenosis (ARAS) represents one of the main causes of secondary hypertension (HTN) and is associated with a higher risk of renal...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC 2026 | ALL-RISE Trial: Coronary Physiological Assessment Using FFRangio

Coronary physiological assessment using pressure-wire techniques (FFR/iFR) carries a Class IA recommendation in ACC/AHA guidelines; however, its use remains limited due to factors such...

ACC 2026 | Protect The Head-To-Head Trial: Randomized Comparison Between Emboliner and Sentinel During TAVI

Ischemic stroke remains one of the most feared complications of TAVI, with a relatively low but persistent incidence of 2–4%, without significant reduction over...

ACC 2026 | PRO-TAVI Trial: Deferring Coronary Angioplasty in Patients Undergoing TAVI

Coronary artery disease is common in patients with severe aortic stenosis undergoing TAVI. Current guidelines recommend considering revascularization in significant coronary lesions, particularly in...